JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Nd:YAG laser treatment for premacular subhyaloid haemorrhage.

Eye 2001 August
PURPOSE: Premacular subhyaloid haemorrhage produces sudden, profound visual loss which may be prolonged if untreated. Nd:YAG laser treatment can create a posterior hyaloidotomy enabling rapid diffusion of subhyaloid haemorrhage into the vitreous gel. This study was performed to assess the results of Nd:YAG laser hyaloidotomy and to compare the outcome with similar conservatively managed cases.

METHODS: Nd:YAG laser hyaloidotomy was performed in 6 patients with premacular subhyaloid haemorrhage. The aetiologies were Valsalva retinopathy, macroaneurysm, branch retinal vein occlusion, proliferative diabetic retinopathy (2 cases) and idiopathic. Four patients with premacular subhyaloid haemorrhage were managed conservatively. The aetiologies were Valsalva retinopathy (2 cases), macroaneurysm and proliferative diabetic retinopathy.

RESULTS: Nd:YAG laser hyaloidotomy achieved rapid resolution of subhyaloid haemorrhage in all treated patients. Visual acuity improved to 6/9 or better in 4 patients, but was limited by ischaemic diabetic retinopathy in 2 patients. No patient had evidence of damage to the retina or choroid from treatment. Among the conservatively managed cases, 3 patients had slow resolution of the subhyaloid haemorrhage over 3-6 months. One patient with diabetic retinopathy demonstrated little improvement at 18 months.

CONCLUSION: Nd:YAG laser hyaloidotomy is a safe and effective procedure. It achieves rapid resolution of premacular subhyaloid haemorrhage with restoration of visual function, preventing the need for vitreoretinal surgery.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app